Genome editing and iPSC-based modeling of the 9p21.3 cardiovascular disease locus shows that it controls large gene networks acting in vascular smooth muscle cells that predispose them to assume atherogenic-like cell states.
INTRODUCTION
Cardiovascular disease (CVD), in particular coronary artery disease (CAD), remains the largest worldwide cause of death. While current therapies focus on addressing the role of cholesterol and lifestyle in CVD, recent human genetic studies have identified a set of $100 genetic variants that influence CAD risk (Nikpay et al., 2015) . Intriguingly, based on tissue expression profiles, many of these variants appear to act in the vascular wall, although no clear mechanisms for this have been defined (Howson et al., 2017) . The first discovered and most impactful CVD risk locus spans an $60 kb 9p21.3 chromosomal region linked to several CVDs, including CAD, stroke, and aneurysms (Burton et al., 2007; Helgadottir et al., 2007; McPherson and Tybjaerg-Hansen, 2016; McPherson et al., 2007; Nikpay et al., 2015; Samani et al., 2007) . In contrast to disease risk mediated by a single causal DNA variant, the 9p21.3 locus comprises two $60 kb haplotypes (risk versus non-risk), which are blocks of $50-100 single-nucleotide polymorphisms (SNPs) in linkage disequilibrium, that segregate together in most non-African populations. In many populations, the frequency of the risk haplotype is $50%. The prevalence and strong additive effect of each copy of the risk haplotype results in an estimated population fraction of 10%-15% of CAD incidence in the United States, thereby representing the largest known genomic source of healthcare costs and lost labor in the United States (Grä nsbo et al., 2013) .
9p21.3-based genetic risk appears independent of cholesterol levels or other known clinical risk factors and is not directly linked to myocardial infarction (Gschwendtner et al., 2009) . Rather, association studies suggest that this risk haplotype acts to promote early events leading to atherosclerotic plaque formation (Bennett et al., 2016; Miller et al., 2016; Motterle et al., 2012) . Vascular smooth muscle cells (VSMCs) are a strongly implicated cell type in this process. During early stages of CAD, mature contractile VSMCs that play key roles in maintaining vascular tone can also de-differentiate into a variety of cell states (sometimes termed synthetic VSMCs) that are more proliferative, less contractile and adhesive, and play key roles in plaque formation and stability (Alexander and Owens, 2012; Bennett et al., 2016) . Indeed, recent mouse lineage tracing studies found that VSMCderived cells can comprise $80% of cells found in plaques, possibly even including foam cells, previously thought to derive solely from the macrophage lineage (Bennett et al., 2016; Shankman et al., 2015) . The 9p21.3 risk haplotype has also been linked to atherosclerotic stroke, as well as other CVDs thought to involve VSMC functions, such as abdominal aortic and intracranial aneurysms (Helgadottir et al., 2008; Dichgans et al., 2014) .
Despite its unique impact on human health, the function of the 9p21.3 risk locus in CAD remains enigmatic. Several factors have hindered efforts to decipher the functional consequences of this region. First, the 9p21.3 CVD genomic region is poorly syntenic in rodents, with clear human synteny emerging only in primates (He et al., 2013; Jarinova et al., 2009; Visel et al., 2010) . Second, this region is a gene desert, lacking known coding genes, with the closest genes being the cell-cycle inhibitors CDKN2A and CDKN2B. Third, although the region encompasses the terminal exons of a long non-coding RNA (lncRNA), ANRIL (also known as CDKN2B-AS1), and is predicted to be enhancer rich, both lncRNA function and enhancer activity are difficult to assess using purely computational tools and are often highly context-dependent (Hannou et al., 2015; Chen et al., 2014) .
To investigate this locus, one group performed a complete deletion of the Cdkn2a/b adjacent region in mice, which is the closest region to the human risk haplotype. These mice exhibited increased tumor incidence, early death, and increased cell proliferation but not atherosclerosis (Visel et al., 2010) . Human correlative studies of 9p21.3 function in various cell types have reported variable and conflicting results. For example, a study of peripheral blood from 1,134 patients with CAD showed that the risk region correlated with increased ANRIL but had no effect on CDKN2A or CDKN2B (Holdt et al., 2010) , while a study of peripheral T cells in 170 healthy donors linked the risk haplotype to reduced ANRIL and CDKN2A/B (Liu et al., 2017) . An additional confounding factor is that ANRIL is extensively alternatively spliced. Because differences in splice isoforms can depend on the cell type and state, this leads to difficulties in directly comparing studies using different ANRIL primer sets in different cell lineages (Hannou et al., 2015; Holdt and Teupser, 2012; Holdt et al., 2011 Holdt et al., , 2013 Jarinova et al., 2009; Motterle et al., 2012) . Given this heterogeneity, performing studies in a strongly implicated cell type such as human VSMCs would likely be most informative. However, such studies have been limited by difficulties in obtaining patient coronary arteries, by the tendency of VSMCs to senesce in vitro and by the known phenotypic heterogeneity of VSMCs across individuals, tissues, and disease states (Almontashiri et al., 2015) .
To overcome these obstacles, we applied genome editing to fully delete the genetically defined CAD risk and non-risk haplotypes (haplotype editing) in iPSCs (induced pluripotent stem cells) and generated a large cohort of 19 isogenic lines. Notably, we achieved efficient homozygous deletion of the entire $60 kb haplotype in iPSCs from risk and non-risk individuals. To precisely define the cellular impact of the locus in disease-relevant cells, while reducing sources of experimental noise, we differentiated iPSCs into VSMCs under identical culture conditions and performed RNA sequencing (RNA-seq) throughout differentiation. These studies identified a network of $3,000 genes that are driven by presence of the risk haplotype and that are implicated in cell proliferation, adhesion, and contraction. Surprisingly, while deleting the risk haplotype nearly completely restored VSMCs to the non-risk state, deletion of the non-risk region had minimal effect, suggesting that the risk haplotype exerts an additive gain of function effect based on only a small number (59-100) of single nucleotide changes across a 60 kb region.
Guided by the transcriptomic results, we functionally tested the VSMCs and showed that risk-dependent VSMCs are phenotypically distinct from non-risk cells and display reduced contraction and adhesion as well as increased proliferation, recapitulating key phenotypes of the de-differentiated synthetic VSMCs found in atherosclerotic plaques. We also identified candidate pathogenic isoforms of ANRIL expressed in risk VSMCs, which, when overexpressed in non-risk VSMCs, induce a synthetic-like cell state. Based on these results, we propose a model in which the 9p21.3 risk haplotype acts additively to increase the propensity for VSMCs to de-differentiate and/or to directly impair mature VSMC functions including adhesion, contraction, and proliferation, thereby influencing risk for CAD and possibly other CVDs. Finally, we show that in VSMCs, the risk locus influences expression of 38 of the 91 known CAD risk genes identified in GWAS studies (Nikpay et al., 2015; Howson et al., 2017) . These studies define a new VSMC-based gene network linking the risk haplotype to a cell state shift in VSMCs involving more than a third of known CAD risk genes, potentially opening the door to new arterial wall-focused therapeutic interventions. Accordingly, this study validates the power of haplotype editing in human iPSCs to uncover new functions of human-specific and non-coding genomic regions relevant to human-specific genome biology and disease.
RESULTS

Efficient Deletion of the~60 kb 9p21.3 Haplotype in iPSCs
To establish the impact of the different 9p21.3 CVD risk haplotypes ( Figure 1A) , we generated iPSCs from CVD patients who were homozygous for the risk haplotype (RR) and from healthy individuals who were homozygous for the non-risk haplotype (NN) ( Figure 1B ; STAR Methods) (Lo Sardo et al., 2017) . The CVD risk locus comprises an $60 kb block of SNPs in linkage disequilibrium ( Figure 1A ; Table S1 ), thus it is unclear which SNPs influence disease risk (Shea et al., 2011) . Therefore, our goal was to delete the entire haplotype (referred to as haplotype editing) (Carroll, 2014) . Precise genome deletions can be generated using zinc finger nucleases, TALENs, or CRISPR/Cas9 type nucleases to induce double strand breaks at two sites of the same chromatid (Lee et al., 2010; Liu et al., 2010) . However, the likelihood of success, maximum size, and reproducibility of large-scale genomic deletions remain poorly defined.
Here, we engineered and tested multiple sets of TALENs and, to provide a control for off-target effects, selected the two independent pairs for iPSC-based editing (Figures 1A and 1B;  Table S1 ; STAR Methods). Both sets of TALENs readily produced the expected $60 k homozygous and heterozygous 9p21.3 deletions, without selectable markers (Figures S1A-S1C and S1E). Homozygous deletion of this locus did not significantly impact iPSC growth rates or pluripotency marker expression ( Figure 1C ). No genes were significantly differentially expressed in isogenic control versus knockout pairs ( Figure 1D ). To sensitively detect phenotypes that could be masked by interhuman genetic variation or by epigenetic variation among iPSCs, we established a large ''test'' set of 19 wild-type (WT) and knockout (KO) isogenic iPSC lines derived from one risk and one non-risk individual using lines edited with both TALEN sets ( Figure 1B ; Table S2 ).
Figure 1. Genome Editing of 9p21 CVD Region in hiPSCs
(A) Schematic of the 9p21.3 CVD risk region, and the approximate cut sites for the two pairs of TALENs (black and blue triangles). The arches denote regions containing the number of SNPs indicated above. (B) Experimental design overview for the generation of isogenic cohorts of 9p21-deleted iPSC lines. Peripheral blood was collected from individuals homozygous risk (RR-red) or non-risk (NN-green) for 9p21.3 CAD-risk region. PBMCs were expanded and reprogrammed into iPSCs. Two independent TALENs sets (a or b) were used to generate isogenic knock out (KO) iPSC lines (open circles) or unedited control clones (filled circles). Nine NN-derived 10 RR-derived total lines were selected for further analysis. (C) Immunocytochemistry for Nanog (green), TRA1-81 (red), and DAPI (blue) in isogenic lines from RR and RR KO, NN, and NN KO. Scale bar, 100 mm. (D) Heatmap of RNA-seq data showing hierarchical clustering of iPSCs based on patient genotype. See also Figure S1 and Tables S1 and S2.
Figure 2. Differentiation of 9p21 KO hiPSCs into Vascular Smooth Muscle Cells and Effect of Deletion on Mesodermal Progenitors
(A) VSMC differentiation protocol for hiPSCs. (B) Immunocytochemistry of VSMC differentiation. Cells stained for NKX2.5 and CNN1-DAPI at day 5 (D5) and a-SMA-Phalloidin-DAPI at D17. Scale bar, 100 mm. (C) Cell count at D5 for the 4 different genotypes. The bar graph shows mean ± 95% CI of three independent experiments. For each experiment, 2-3 lines were used per genotype. *p < 0.05; **p < 0.001: ***p < 0.0001 one-way ANOVA-Bonferroni. (D) DNA content analysis at D5 performed by propidium iodide staining followed by cytofluorimetric analysis. Graph shows the S/G2 ratio. Scale bar is mean ± SD. *p < 0.05, *p < 0.01 one-way ANOVA-Bonferroni.
The 9p21.3 Risk Haplotypes Differentially Affect VSMC Precursors
Next, we optimized an established method to differentiate VSMCs from iPSCs (Cheung et al., 2014) . This method produces mesodermal progenitor-like cells (MP) that then can be induced to mature into VSMCs (Figure 2A ). All iPSCs in the cohort produced MPs and VSMCs based on staining for key cell type markers ( Figures 2B, S2A , and S2B). The haplotypes or their deletions did not impact differentiation, although we detected a small decrease in alpha-SMA + cells in NN KO cells at day 17 (Figure S2A) . In contrast, proliferation rates of the MPs were impacted by the 9p21.3 haplotype such that RR WT MPs proliferated more rapidly than NN cells. Unexpectedly, deleting the risk region in RR cells reverted their proliferation to that of NN WT MPs, while deleting the non-risk region in NN cells had no effect (Figures 2C, 2D, and S2A) .
To evaluate the global impact of the 9p21.3 CVD locus, we performed an extensive set of RNA-seq experiments at three stages of differentiation for 14 different iPSC lines. To ensure consistency, multiple lines from each genotype were profiled in at least three independent biological experiments over the course of more than a year (Table S2 ). Principal component analyses (PCA) and clustering show that, as in the iPSCs, MP cells primarily cluster based on the donor, but suggest a trend in which the RR KO cells begin to resemble the NN and NN KO cells (Figures 2E and S2C) . On day 3 of VSMC differentiation, deleting the 9p21.3 region in NN cells affected only three genes ( Figure 2F ). Of these genes, two are the neighboring CDKN2B and CDKN2A genes and the third is NNAT, which is an imprinted gene thought to be frequently misregulated in iPSCs.
In contrast, deleting the haplotype in RR cells resulted in differential expression of 113 genes ( Figure 2F ). This was surprising because the haplotypes differ by only 59-100 SNPs. These genes were linked to gene ontologies including developmental processes, system development, ectoderm development, and cell-cell adhesion ( Figure 2F ). Comparing the RR cells with the three other groups (RR KO, NN, and NN KO) identified 1,785 differentially expressed genes that are enriched in GO categories including embryo development, muscle development, and cell adhesion ( Figure S2D ; Table S3 ). While deletion of the risk or non-risk haplotypes both reduced CDKN2B expression, we did not detect differential expression of CDKN2A or ANRIL between the RR and NN cells.
The 9p21.3 Risk Haplotypes Differentially Impact Gene Expression in VSMCs
The gene expression differences in MP cells suggested that their more mature VSMC progeny might exhibit functional and transcriptional deficits that could shed light on CVD. Analyses of day 17 VSMCs revealed a striking difference between RR cells and RR KO cells (3,268 genes), while deletion of the NN region had only a modest effect (87 genes) ( Figures 3A and S3A ).
Remarkably, deletion of the RR haplotype restores the VSMCs to a transcriptional state resembling that of the NN and NN KO VSMCs, as shown by PCA ( Figure 3B ). The magnitude of this transcriptional change is on par with those seen between cells of different subtypes, suggesting that the risk locus may induce a cellular phenotypic switch, similar to those that VSMCs undergo in the vascular environment when inflammatory signals convert VSMCs from contractile cells to alternative fates, such as synthetic VSMCs (Alexander and Owens, 2012; Rensen et al., 2007; Bennett et al., 2016) .
Analyses of this candidate gene regulatory network showed that the dysregulated genes are likely involved in cell cycle, DNA replication, and repair as previously reported (Figures 3C and S3B) (Motterle et al., 2012; Almontashiri et al., 2015) , supporting the relevance of the model system. However, we also identified several novel candidate functional changes based on their enrichment in gene ontologies such as cell adhesion, muscle development, and muscle contraction (Figures 3C-3E; Table  S3 ), which might also be expected to play roles in CAD. Mapping the differentially expressed genes to the genome showed that they are distributed across all chromosomes with no enrichment proximal to the 9p21 locus ( Figure S3C ), indicating that the risk haplotype in VSMCs can regulate genes in trans, either directly or indirectly.
VSMC Function Is Perturbed by the CVD Risk Haplotype
Guided by the RNA-seq analyses, we performed functional tests on sets of isogenic VSMCs using bioengineering and pharmacologic approaches. As predicted, mature RR VSMCs proliferated more quickly than NN VSMCs, while deleting the haplotype restored normal proliferation ( Figure S3D ). Next we measured VSMC contractile force using traction force microscopy (TFM) (Del Alamo et al., 2007) ( Figure 4A ), which quantifies the ability of cells to displace fluorescent beads embedded in a hydrogel. TFM showed that all cells maintained polarized traction forces ( Figure 4B ), but RR VSMCs exerted markedly lower traction forces than the three other genotypes ( Figure 4C ). Next, we quantified adhesion strength using a spinning disc assay in which cells are exposed to a range of stress forces depending on their radial position ) ( Figure 4D ). RR cells exhibited weaker adhesion than NN cells with or without the deletion ( Figure 4D ). In both cases, deleting the RR locus restored normal function ( Figures 4C and 4D ).
In addition, we measured collective VSMC behavior in a collagen gel-based contraction assay that is compatible with pharmacologic studies. Again, the RR WT lines were outliers, exhibiting reduced contraction compared to the NN WT and NN KO lines. Deleting the risk haplotype restored contraction of the RR lines to levels of the NN lines ( Figure 4E ). These results could indicate that the RR cells are simply unhealthy or have lost the capacity to function as VSMCs. To test this, we employed pharmacologic agents that stimulate (bradykinin) or impair contraction (cytochalasin D) ( Figure 4F ). Bradykinin can restore gel contraction (E) Principal component analysis (PCA) analysis of the whole transcriptome at D3. (F) Heatmaps of genes differentially expressed (p-adj <0.05) between NN and its isogenic KO lines and RR and its isogenic KO lines. Legend of value is Z score. Details for number of samples used can be found in Table S2 . See also Figure S2 and Table S3 . Right: bar chart of GO term analysis of genes differentially expressed in RR VSMCs versus the other three groups. GO terms are listed based on fold enrichment, with the relative Bonferroni p value above, the number inside the column is number of genes differentially expressed in each term. GO categories with more than 2-fold enrichment are listed.
(legend continued on next page) capacity to RR WT VSMCs to a degree similar to NN, NN KO, or RR KO cells, indicating that they possess but do not use their contractile capabilities. Conversely depolymerization of the cytoskeleton with cytochalasin D significantly reduced contraction for all VSMCs. These analyses indicate that the RR cells maintain key functional properties of VSMCs, while exhibiting an altered cell state, and offer proof of principle that the effects of the risk locus can be reversed through pharmacologic intervention.
The Risk-Haplotype Alters ANRIL Expression How might the risk haplotype induce the large transcriptional and functional phenotypic differences we observe in VSMCs? Although lacking known coding genes, the 9p21 risk interval contains the terminal exons of the lncRNA ANRIL (CDKN2B-AS1). Yet, none of the SNPs in this region fall into exons or (D and E) Heatmaps showing differentially expressed (fold change >2) genes from GO term categories shown in (C) . (D) Heatmap includes genes present in the following categories: heart development, muscle contraction, and muscle organ development. (E) Heatmap shows genes differentially expressed in the biological adhesion category. Values are Z score. See also Figure S3 and Tables S2, S3 , and S6. (B) Tangential strain energy maps resulting from SMC traction forces on 11 kPa hydrogels. Representative heatmaps of each genotype shown. Scale bar, 50 mm. (C) TFM assay: total strain energy normalized to cell area was plotted for VSMCs of varying genotypes (n > 25 in each assay; mean ± 95% CI). ***p < 0.001 one-way ANOVA-Bonferroni. (D) Spinning disc assay for VSMCs of varying genotypes (n > 10 in each assay; mean ± 95% CI.). Each data point is a biological replicate derived from the t 50 of a sigmoidal fit of multiple technical replicates. **p < 0.01 one-way ANOVA-Bonferroni. (E) Gel-based contraction assay during a time course of 8 days (mean ± SD). **p < 0.01, ***p < 0.001 one-way ANOVA each time point. Statistics represent RR lines versus RR KO. NN versus NN KO (ns). (F) Gel-based contraction assay after pharmacological treatment with Bradykinin (10 nM) or cytochalasin D (0.5 mM). Plot shows data at D8 of treatment (mean ± SD). Statistics show one-way ANOVA-Bonferroni for NT versus bradykinin and NT versus cytochalasin D for each genotype, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4 and Table S2. canonical splicing regions (Harismendy et al., 2011 ) ( Figure 1A ). Previous studies have uncovered extensive ANRIL alternative isoform usage, including circular isoforms, which can vary based on cell type, culture conditions, and/or the donor genetic background (Holdt et al., 2013 (Holdt et al., , 2016 Holdt and Teupser, 2012; Hannou et al., 2015) . Our isogenic lines and RNA-seq datasets provide a unique resource to assess ANRIL isoform expression levels in a particular cell type or lineage, under controlled culture conditions.
While previous studies used PCR across various exons to measure ANRIL levels, here, we made use of the RNA-seq data to perform an unbiased analysis of potential splice junctions found in day 17 VSMCs. This identified a set of predicted ANRIL junctions, leading to several candidate isoforms for each group of VSMCs ( Figures 5A, S4A , and S4B). These alignments indicate that ANRIL isoform usage differs between the RR and NN lines. Specifically, in RR cells we observed enhanced splicing to an alternative terminating exon (13) that results in production of short ANRIL isoforms, while no splicing to exon 13 was detected in NN cells. In contrast, both NN and RR VSMCs exhibited splicing to the alternative terminal exon 19, which is found in Figure 5 . Differential Expression of ANRIL isoforms in 9p21 RR VSMCs (A) Schematic of predicted short (terminating in exon 13) and long (terminating in exon 19) ANRIL isoforms based on mapping RNA-seq reads across exon junctions. *, indicates termination sites; ?, indicates putative junctions, not detected in RNA-seq reads. (B) Time course qRT-PCR of ANRIL expression during VSMC differentiation. Graphs show expression level of ANRIL transcripts using primers spanning two different exon-exon junctions: 18-19 (left, long isoforms), 6-7 (right, short and long isoforms). PPIA was used as housekeeping gene. Graphs show mean ± 95% CI. **p < 0.001, ***p < 0.0001 one-way ANOVA-Bonferroni for each time point.
(legend continued on next page) long ANRIL isoforms (Figures 5A, S4A, and S4B). We note that some of the splice junctions we observed have not previously been reported, highlighting the potential complexity and context dependence of ANRIL splicing. However, due to the relatively low coverage of the upstream exons, this analysis is not likely a complete description of ANRIL isoforms in VSMCs.
To address this question using a second method, we employed a reverse transcription (RT)-PCR approach using template switching which confirmed the presence of two previously described short isoforms (11 and 12), and also detected a long isoform resembling previously described isoform 2, although with some subtle differences ( Figure S4C ) (Hannou et al., 2015; Holdt et al., 2013) . We note that due to low expression levels and the potential for PCR-based jackpotting, these studies are not expected to be quantitative. We were unable to detect any of the previously described circular ANRIL isoforms, using RNA-seq alignments, bioinformatics methods to detect circular RNAs (STAR Methods) or real-time PCR-based assays (Holdt et al., 2016) .
Next, we performed qRT-PCR using primers designed to detect the long isoforms (exons 18-19). As expected, long isoform expression is absent in KO VSMCs ( Figure 5B ). Long ANRIL isoforms levels are very low in iPSCs but increase throughout VSMC differentiation and are similar in RR and NN cell lines. In contrast, exons found both in the short and long isoforms (exons 5-6 or 6-7) increase throughout differentiation, but are more highly expressed in RR VSMCs ( Figures 5B and S4D ). This suggests that short isoforms are selectively increasing, as predicted by the RNA-seq alignments. We also directly examined expression of short ANRIL isoforms containing exon 13, confirming that the RR cells express higher levels than NN cells ( Figure S4D ).
ANRIL Expression in Non-risk VSMCs Partly Recapitulates the RR Phenotype
These expression studies support a model in which presence of the risk haplotype leads to increased expression of short ANRIL isoforms in RR cells relative to NN cells when they are differentiated into VSMCs in vitro. To test the effect of short ANRIL expression, we cloned isoforms 11 and 12 into inducible lentiviral expression vectors and expressed them during VSMC differentiation of NN KO cells ( Figures 5C and S4E ). Expressing the short ANRIL isoforms induced morphologic changes in mature NN VSMCs, inducing them to closely resemble the RR cells ( Figure 5D ).
qRT-PCR analyses of the top 12 differentially expressed genes (between NN, NN KO, RR KO, and RR) that are involved in adhesion and contraction (based on GO term analyses) showed that expressing the exogenous short ANRIL isoforms in NN KO cells reduces expression of all six genes that are lower in RR VSMCs compared to NN VSMCs, consistent with these isoforms promoting VSMC cell fate plasticity ( Figure 5E ). In contrast, ANRIL expression only increased levels of one of the six tested genes (CD36) that are elevated in RR VSMCs. However, this gene is of particular interest because it is an oxidized low density lipoprotein receptor with known relevance to atherosclerosis (Park, 2014) . To determine whether short ANRIL expression can affect VSMC function, we performed single cell contraction assays using traction force microscopy (TFM). Strikingly, we show that misexpression of short ANRIL in mature NN VSMCs reverts their phenotype and reduces their capacity to exert contractile force, such that they resemble the RR cells (Figure 5F) . These experiments delineate novel roles for ANRIL expression in controlling VSMC phenotypic diversity. However, the incomplete recapitulation of all gene expression changes suggests that the effect of the entire risk haplotype effect may encompass more than the effects of short ANRIL expression.
Confirming Key Phenotypes in iPSC Lines from Different Individuals By constructing and analyzing a large test set of isogenic haplotype-edited iPSC lines, we uncovered an unexpected additive gain-of-function role for the 9p21 CVD risk haplotype in VSMCs.
To confirm these findings in other individuals, we generated a replication set of iPSCs from five additional RR and NN individuals bringing the total number of genetically distinct donors to seven (4 independent RR individuals and 3 NN; Table S2 ). We also produced RR KO cells from an additional donor ( Figure 6A ; Table S2 ). Using these new lines, we performed VSMC differentiations and tested the cells using the TFM and spinning disk adhesion assays previously described ( Figure 6B , n = 22 total iPSC lines). In all assays, we observed statistically significant risk haplotype-dependent differences in replication set. We also confirmed that deletion of the risk haplotype is sufficient to restore contractile and adhesive function to VSMCs from a second risk individual ( Figure 6B ).
We next examined ANRIL expression in the new lines. As before, qRT-PCR experiments detected higher expression of ANRIL exons 6-7 (found in all isoforms) compared to exons 18-19 (long isoforms only) in all RR lines compared to all NN lines ( Figure 6C ). The unbiased non-quantitative analyses of short ANRIL isoforms identified isoforms 11, 12, and 13 in RR lines, although at differing relative ratios in different amplifications of independently constructed libraries from the same RNA, likely due to the ''jackpotting'' effect known to arise in PCR-based analyses of limiting samples ( Figure S5A ). In the two of the NN lines, we detected no short isoforms, while in one of the two other NN lines, we detected isoforms 11, 12, and 13. However, we did not detect increased levels of exons 6-7 in this line in qRT-PCR assays ( Figure 6C ), suggesting that these products are present at (C) Table S2 . very low levels, consistent with our previous analyses of exon 13. We also detected several minor products that appeared to be novel ANRIL isoforms, though these could also be immature splicing forms or PCR-based artifacts. These studies highlight the potential complexity of ANRIL splicing as it relates to cell type.
Finally, we performed qRT-PCR analysis of eight genes related to adhesion and muscle contraction that we identified as the most significantly differentially expressed in RR versus NN VSMCs based on RNA-seq. These patterns of differential gene expression were consistent in the five new donor-derived iPSCs, with six meeting statistical significance and two (CD36 and ROBO2) exhibiting a trend that was not statistically significant ( Figure S5B ). Given the known heterogeneity in the behaviors of non-isogenic iPSCs (Carcamo-Orive et al., 2017; DeBoever et al., 2017) , and known donor specific-effects on gene expression, these results support a strong and consistent role for risk haplotype status in governing the attributes of in vitro-derived VSMCs, acting partly through increased ANRIL expression.
9p21.3-Dependent Gene Networks Are Enriched in CVD Genes and Pathways
The mechanisms leading to increased risk for CVD can be inferred from genes identified in GWAS and other genomic studies. A recent large scale meta-analysis from the CARDIoGRAMplusC4D consortium (Nikpay et al., 2015) identified 73 independent loci associated with CVD, which have since been expanded to Table S2. encompass 15 new risk loci (Howson et al., 2017) . The expression patterns of the genes near these SNPs led the authors to propose a strong role for vascular wall cells, such as VSMCs in CVD genetic risk. Therefore, we examined the expression of these genes in our original isogenic RNA-seq dataset of haplotype-edited lines. Remarkably, 38 of the 91 of the genes associated with the 88 risk loci are dysregulated in VSMCs in the context of RR haplotype, which is a highly significant overlap (p = 0.0019, binomial distribution) (Figures 7A and 7B) . Identifying this unexpected cell state and genotype-dependent transcriptional network of CAD risk genes that act in VSMCs represents a promising new avenue for clinical studies aimed at vascular wall-based mechanisms.
As the previous analysis shows, the large number of differentially expressed genes can constitute an important resource for understanding VSMC biology and CAD. To further explore gene networks regulated by the 9p21.3 risk haplotypes, we performed network analyses using ingenuity pathway analysis (IPA) and identified pathways affected by genes that differ between RR VSMCs and the other three genotypes (RR KO, NN, NN KO), using a control set of genes expressed at similar levels in these cells (Table S4 ) (Krä mer et al., 2014) . The most enriched pathways included Rho family GTPase signaling, integrin signaling, and actin cytoskeleton signaling, (Figures 7C  and S6; Table S4 ), which are all pathways involved in de-differentiation of VSMCs. Many of these genes have also been previously implicated in CVD, based on the IPA Disease and Function Database (Figures 7C, S6B, and S6C) . In contrast, only one canonical pathway was identified as enriched in the control gene set (PI3K/AKT signaling) (Table S4) , providing evidence that the differentially expressed genes are relevant to specific aspects of VSMC function related to cell state and CAD.
To link these pathways directly to effects on human vascular cells affected by CAD, we examined the results of a recent integrative genomics analysis of human coronary artery tissues derived from samples of affected individuals. This comprehensive study identified several key nodes of convergence for epigenetic and transcriptomic differences correlating with disease states with the strongest convergent node being AP1 signaling (Miller et al., 2016) . The most significant IPA pathway related to risk haplotype-dependent genes (Rho family GTPase signaling), also converges on AP1 signaling, directly linking the 9p21.3 regulated pathways to markers identified in diseased human arterial samples ( Figure 7C ). Other dysregulated genes such as TCF21, PECAM1, and PDGFR have previously been identified in GWAS studies and/or diseased human tissue (Miller et al., 2016) .
IPA can also construct de novo networks based on lists of affected genes. We performed a de novo network analysis on the set of genes differentially expressed in the RR cells versus NN and RR/NN KO cells, again using the control gene set for comparison. The networks derived from the differentially expressed gene list are enriched in genes related to CVD, cellular movement, cell morphology, cell-to-cell signaling, cellular compromise, cellular function, and maintenance and similar terms, while the control gene list networks were not ( Figure S7 ; Table S5 ). Notably, some of the molecules in the network are also genes that we described previously as being directly altered by ANRIL overexpression in NN KO cells and which are known to play key roles in coronary artery disease (i.e., CD36, LAMC2, FN1, ITGA3). Together these analyses predict that gene expression differences in iPSC-derived VSMCs can be used to identify and understand gene expression networks related to disease in mature arterial wall cell types in vivo and, also, unexpectedly, link genes identified in association studies into transcriptional networks that appear to correlate with distinct VSMC states.
DISCUSSION
Human population genomic studies frequently identify genomic risk regions that are difficult to study due to a lack of coding SNPs, large blocks of linkage disequilibrium that prevent statistical disentanglement of linked variants, and/or inherent difficulties in modeling subtle genetic differences between humans with animal models. Here, we provide proof-of-principle that it is feasible to interrogate the function of these regions by performing homozygous deletion of large blocks of the human genome in iPSCs. This strategy offers advantages over analyses of large numbers of human primary cells derived from people of widely varying medical histories, ages, and genetic backgrounds as it significantly reduces most sources of background variation. This, in turn, increases the sensitivity of the assays, enabling comprehensive discovery of genetic changes driven by the risk haplotype. Indeed, the number of differentially regulated genes we have uncovered ($3,000) (Table S6 ) is significantly greater than those reported using gene chip-based profiling of human cell lines ($200-700) (Holdt et al., 2013) . In addition, the expression differences we identify are large enough to detect significant enrichments in known CVD-related pathways and gene networks. As such, this study establishes the power of haplotypeedited iPSCs to identify the functional consequence of genetic variation in defined human cell types.
A second key advantage of the study design is the use of an independent replication set of iPSCs to confirm the key cellular and transcriptional phenotypes we observed in the initial test set. Importantly, we were able to demonstrate statistically significant haplotype-dependent differences in each assay we performed. This predicts that the effects of the haplotype may be robust and not strongly influenced by common genetic variation, though additional larger scale studies are needed to confirm this. Furthermore, unlike genetic variants that influence the expression of only a single gene and therefore have many potential genetic sources of subtle variation, the 9p21.3 haplotype-dependent effects encompass a very large network of genes and pathways for which we have demonstrated functional relevance.
Mechanisms Linking 9p21.3 Haplotypes to Cellular State Changes
How might the relatively small number of single nucleotide changes between the major 9p21.3 haplotypes ($59-100 SNPs in a $60 kb region) lead to such a drastic cellular phenotypic switch in VSMCs, while having no significant impact on iPSCs? Intersecting our dataset with several recent integrative genomics and epigenomic studies suggest an attractive model. Our data suggest that the risk haplotype may contain SNPs that alter the function of enhancers that increase ANRIL expression (compared to the non-risk haplotype) because deleting the risk (but not non-risk) haplotype (ANRIL exons 10-19) reduces expression of the remaining upstream ANRIL exons (1-9) (Figure 5) . Intriguingly, a recent paper examining long-range chromatin interactions showed that non-coding candidate regulatory regions within the 9p21.3 risk haplotype associated more strongly with the ANRIL enhancer (and also with the nearby CDKN2B enhancer) compared to the analogous region in the non-risk haplotype (Mumbach et al., 2017) . This mechanism could explain at least part of the phenotype we observe, since we can mimic several key cellular and molecular phenotypes in NN KO cells via ANRIL overexpression. The failure of ANRIL overexpression to fully recapitulate the RR phenotype in NN KO cells is consistent with the possibility that additional variation in the 9p21.3 risk region may also influence cellular function, perhaps through additional enhancer regions, although this may also be due to technical issues.
The design of this study provides both correlative and causative evidence for the role of ANRIL in VSMCs and their mesodermal precursors. As ANRIL expression increases during iPSC to VSMC differentiation, the magnitude of the transcriptional shift grows. This suggests a causal role for ANRIL expression, which we confirm in NN KO cells through overexpression. These observations immediately pose the question of how increased ANRIL expression might trigger the global transcriptional changes we observe. One possibility, suggested by previous studies (Hannou et al., 2015) , is that ANRIL expression, acting in cis, represses the CDKN2B/A genes, thereby inducing proliferation that, in turn, leads to a cellular phenotypic switch. However, our data are not fully consistent with this model because we observe lower CNDKN2B levels in NNKO and RRKO cells compared to NN cells, yet they have the similar proliferative phenotypes. We can also switch the phenotype of mature NN VSMCs through overexpression of ANRIL isoforms. Therefore, our data support a direct role variation at the risk locus and/or ANRIL in globally regulating gene expression and cellular function.
A second possibility is that, as reported previously, ANRIL interacts with polycomb group proteins (Devaux et al., 2015) . While in previous studies, this interaction was reported only for genes in the vicinity of ANRIL, it remains possible that these interactions could act more broadly throughout the genome, or that cis interactions could trigger a more global transcriptional cascade resulting in the changed expression of $3,000 genes. A third model could rely on the known capacity of long non-coding RNAs to act as sinks for regulatory microRNAs (Xu and Zhang, 2017) . Future studies will be required to test these and other possible models.
Links to Cardiovascular Disease Mechanisms
While production of iPSC-derived VSMCs in vitro is unlikely to precisely mimic the events involved in CAD onset and progression, the cellular phenotypes we observe suggest an attractive model to explain how the 9p21.3 risk haplotype might influence CAD, stroke, or associated aneurysms through its action in VSMCs. In CAD, VSMCs are known to de-differentiate into a less contractile, less adhesive, and more motile cell state, termed the synthetic phenotype, which itself encompasses several functionally diverse cell states (Alexander and Owens, 2012; Rensen et al., 2007) , CAD is also accompanied by the accumulation of inflammatory foam cells in atherosclerotic plaques (Libby et al., 2011) . Intriguingly, although foam cells were traditionally thought to be derived from macrophages, lineage tracing studies in mice have shown that VSMCs can serve as a major source of foam cells (Alexander and Owens, 2012; Shankman et al., 2015) suggesting that VSMC cell fate plasticity could underlie CAD.
Here, we show that iPSC-derived human VSMCs carrying the risk haplotype exhibit several phenotypes consistent with this model. The RR VSMCs exhibit a large set of global changes to the cellular transcriptome that correlate with increased proliferation and decreased adhesion and contractile force in mature VSMC-like cells. Reduced VSMC adhesion and contraction as a result of the 9p21 risk haplotype may also be a reasonable explanation for concurrent increased risk for abdominal aortic and intracranial aneurysms, all which involve arterial wall regions that are under high shear stress. Finally, the datasets we have generated through comprehensive genome-wide transcriptomic profiling of this large set of haplotype-edited isogenic iPSCs supply a set of candidate targets and CAD-relevant pathways and mechanisms that may be explored in broader patient populations and clinical settings.
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The cell line numbers correspond to the following accession numbers in WiCell: C00512 (SCRP0517i), C568-1 (SCRP0601i), C664-9 (SCRP0709i). HE463 (SCRP2307i), HE787-3 (SCRP2503i), C939-2 (SCRP0802i).
METHOD DETAILS
Peripheral blood mononuclear cell isolation and culture PBMC isolation from blood in Heparin vacutainers was performed using Ficoll-PaquePremium (GE Healthcare, cat #17-5442-03). Blood was diluted with 10 mL 1X PBS, layered over the top of 20 mL Ficoll and then centrifuged at 750xg for 35 min with the acceleration at its lowest setting. The white interphase (buffy coat) between the plasma and Ficoll fractions was transferred into 35 mL 1X PBS and centrifuged for 10 min at 350 xg. The cells were then resuspended in 10 mL 1X PBS and centrifuged for 10 min at 250 xg. Cells were resuspended in 10% DMSO in heat-inactivated FBS (Life Technologies, cat # 10082139), frozen at À80C and then transferred to liquid nitrogen for long-term storage.
PBMC reprogramming to iPSCs iPSCs were generated from donors via Yamanaka episomal-based reprogramming of peripheral blood mononuclear cells (PBMCs) (Lo Sardo et al., 2017) . Isolated and cryopreserved PBMCs were thawed and cultured for 12-14 days in Mononuclear Cell (MNC) complete medium (MNC basal medium (IMDM (GIBCO Cat#21056023), Hams F12 (GIBCO Cat#31765035), Glutamax (GIBCO Cat#35050-061), Chemically Defined Lipid Concentrate (GIBCO Cat#11905031), ITS-X (GIBCO Cat#51500-056), 1-Thioglycerol (Sigma, 435uM), Bovine Serum Albumin (Sigma Cat#A9418, 0.5%w/v), and Ascorbic acid (Sigma Cat#A8960, 50ug/mL)) supplemented with rhEPO (R&D 2U/mL), hSCF (R&D 50ng/mL), rhIGF1 (R&D 40ng/mL), hIL3 (R&D 10ng/mL), Dexamethasone (Sigma Cat#D2915 1uM), and Holo-transferrin (R&D 50ug/mL)). Cell count was performed at feeding on Days 2, 5, 8, and 11, with cells seeded at 2.5x10 6 cells/mL for days 2-5, and 1.5x10 6 cells/mL on days 8 and 11. After 14 days of expansion 2x10 6 cells were transfected (Amaxa Nucleofector Technology) with plasmids containing the reprogramming transcription factors (pCXLE-hOCT3/ 4-shp53; pCXLE-hSK; pCXLE-hUL), 2ug each plasmid. Human CD34+ cells nucleofector kit (Cat#VPA-1003) was used with program U-008 on an Amaxa Nucleofector II device. Cells were allowed to rest in MNC complete medium for 2 days, then plated on inactivated MEF feeders (3x10 4 cells/cm 2 ) in MNC basal medium supplemented with 10% FBS, and transitioned to mTeSR1 medium (Stemcell Tech Cat#05850) over the next 3 days. Cultures were fed with fresh mTeSR1 on days 7, 9, and daily thereafter. From Days 10-20, 50% fresh mTeSR was supplemented with 50% fibroblast conditioned mTeSR (inactivated human foreskin fibroblasts (EMD Millipore Cat#SCC057)). Medium was supplemented with the small molecule enhancer of reprogramming sodium butyrate (0.25mM) as nascent colonies became visible with timing varying on a patient-by-patient basis, typically around Day 13. Colonies were allowed to develop until approximately 22 days post-transfection and then picked to feeder-free conditions on Matrigel (Corning Cat#354277), at which time sodium butyrate supplementation was stopped.
Induced pluripotent stem cells culture and characterization
Induced Pluripotent Stem Cells (iPSCs) were cultured in Matrigel-coated plates (Greiner Bio-one Cat#657160) with mTeSR medium. Cells were passaged every three to four days using 0.5mM EDTA as the dissociation reagent. PBMC-derived iPSCs were characterized after approximately 8-9 passages in culture. Karyotyping analysis was performed by Infinium HumanCore BeadChip. Validation of the iPS cells was performed by immunofluorescence staining and flow cytometry. 250,000 fixed cells per sample were incubated at room temp for 30 minutes in Blocking Buffer (5% heat inactivated FBS in 1XPBS, -Ca, -Mg). SSEA4 (Stemgent, Cat#09-0003, use 1:5) and TRA 1-60 (Millipore, Cat# MAB4360, use 1:100) were added to samples individually and incubated for 30 minutes RT. Three washes were performed with 1% heat inactivated FBS in 1XPBS, -Ca, -Mg. After the final wash, the SSEA4-stained samples were resuspended in 500 ul of Wash Buffer and transferred to FACS tubes. The TRA 1-60 samples were then resuspended in Goat anti-mouse-IgM Alexa 488 (Life Technologies, Cat#A21042, use 1:200) secondary, and incubated 30 minutes RT. Three washes were performed using the wash buffer listed above. The cells were resuspended in 500ul wash buffer and transferred to FACS tubes. The samples were read and analyzed on the LSR II. The LookOutâ Mycoplasma PCR Detection Kit (Sigma, Cat. # MP0035) was used to check for Mycoplasma contamination, following the manufacturer's instructions and using JumpStart Taq DNA Polymerase (Sigma, Cat #D9307).
Genome editing, transfection, genotyping
Transcription activator-like effector nucleases (TALENs) for the 9p21 CAD risk region were designed using an archive of TALE modules as described , and cloned into a mammalian expression vector as fusions to obligate heterodimer forms of the FokI endonuclease (Doyon et al., 2011) bearing a TALE-FokI linker optimized for gene editing of endogenous loci in mammalian cells. The deleted region was designed to encompass all SNPs previously reported to be associated with coronary artery disease (rs1333039 (chr9:22065658) to rs1333049 (chr9:22125504). The flanking $5kb of these SNPs was tiled with TALENs to select the of RNasin Plus Thermostable RNase-Inhibitor (Promega), and template switch oligo (1uM final concentration) was added and mixed with annealed RNA on ice. The samples were placed into preheated to 42C thermocycler, and the following program run: 42C-30min; 2cycles of: 20C-5min, 42C-5min, 55C-10 min, 65C-5 min; 4C-hold. First round of PCR amplification was done by adding: 25uL Kappa HiFi ready mix (2x), 0.8uL 50uM ISPCR primer, 4.2uL H2O. Run program as follow (Dropseq protocol): 95C-3 min; 4cycles: 98C-20sec, 65C-45sec, 72C-3min; 9 cycles:98C-20sec, 67C-20seC, 72C-3min, 72C-5 min, 4C -hold. The library was cleaned with 1x AmpureXP beads and eluted in TE. Secondary PCR amplification was done with exons' specific primers with touchdown program: 98C -1min; 8cycles: 98C-15sec, 68C-15sec (auto-delta À0.8 every cycle), 72C-3min; 34cycles: 98C-15sec, 60C-15sec, 72C-3min, 72C-3min, 4C hold. 10ng of RACE library was used as template. Primer pairs used: Exon1_fw -Exon13_rev. Complete list of primers in Table S6 . The products were visualized on 1% agarose gel. The bands were cut and extracted using Zymo Gel DNA purification kit protocol with double wash with 750uL of DNA wash buffer.
ANRIL isoform overexpression
Reference isoforms 11 and 12 of ANRIL were ordered via gBlocks from IDT Inc. and minimal CMV promoter and KpnI and BsrGI digestion sites were added to the fragments by two rounds of PCR with Q5 polymerase, digested and inserted into 3 rd generation lentiviral vector with tetracycline response element and truncated HIV 3 0 LTR. For lentivirus generation, LentiX HEK293T cells (Clontech inc.) at 70% confluency were transfected with 3 rd generation packaging vectors (REV, RRE and pMD 2.G) and ANRIL plasmid using calcium phosphate method. 24 hours after transfection the media was changed to DMEM 10% FBS, supplemented with sodium pyruvate and nonessential amino acids and 1.1g/100ml of lipid free BSA (Sigma Aldrich). Virus was harvested 48h after transfection, filtered through 0.45um low protein binding syringe filters (Millipore) and concentrated using LentiX concentrator (Clontech) according to the manufacturer instructions. The pellets with the virus were resuspended in CDM-PVA media. NN KO cells at D13 of VSMC differentiation were co-infected with lentiviruses containing rtTA M2.2 and TetO_ANRIL 11 or 12. After 24 hours, 100ng/ml of doxycycline were added to the media to induce ANRIL expression. After D17 cells were maintained in VSMCs media with doxy for 4 more days. Cells were maintained in culture without doxy for 4 passages (about 20 more days). RNA was collected at passage 1, 2 and 4.
Deep sequencing and analysis of CAD Risk region
The region was divided into three parts 25, 25, and 16kb and each of them was amplified from genomic DNA using PrimeStar GXL enzyme using the following program: 98C -1min; 8cycles: 98C-15sec, 68C-30sec (auto-delta À1every cycle), 68C-15min; 34cycles: 98C-15sec, 60C-30sec, 68C -15min; 72C -3min;4C -hold.
The fragments were separated on 1% low melt agarose (Biorad) and purified by Agarase (NEB) treatment and isopropanol precipitation. The PCR products were tagmented and amplified using NexteraXT (Illumina inc.) library preparation kit according to the manufacturers instructions. Fragments 550-600bp were selected using Bluepippin Prep (Sage Science) and sequenced with MiSeq using 2x300bp reads. The reads were aligned using Bowtie2 aligner and calls visually made using IGV.
RNA-seq data analysis
Adaptor sequences were removed using Trimmomatic PE v0.32. (Bolger et al., 2014) . Reads were aligned using STAR aligner v2.3.0 (Dobin et al., 2013) to the human genome (hg19) and UCSC Genes reference transcriptome with default parameters. Read counts per gene were quantified with HTseq. (Anders et al., 2015) . To remove genes with low expression levels, raw read counts were transformed to counts per million (CPM) and averaged within groups being compared. Genes with CPM values below 10 on average were excluded from the enrichment analyses and heatmaps. For differential expression analysis, raw counts were normalized using the variance stabilizing transformation and differentially expressed genes were identified using the DEseq function implemented in the DESeq2 R package (v1.8.2) (Love et al., 2014) . For identification of ANRIL splicing junctions, we used samtools 1.3 (Li et al., 2009) to pool STAR aligned reads and IGV 2.3.80 (Integrative Genomics Viewer) (Thorvaldsdó ttir et al., 2013) for visualization. A minimum of two reads must span a junction. For visualization batch effects were removed by the COMBAT function from the SVA R package (Surrogate Variable Analysis v3.18.0) (Leek et al., 2012) ). The heatmaps were made using gplots. Principal component plots we generated with the rgl and pca3d R packages. Gene Ontology analysis was performed by using Panther Classification System (version 10.0 Released 2015-05-15) (Mi et al., 2013 (Mi et al., , 2016 (and DAVID Bioinformatics Resources 6.7) (Huang et al., 2009a (Huang et al., , 2009b .
Methods for detection of circular RNA from RNA-seq datasets
The reads that were trimmed by Trimomatic as described before, were aligned using STAR aligner with parameters recommended by DCC package for paired and unpaired reads, as described on DCC's github page. The DCC package was executed without -R option to increase sensitivity. DCC @samplesheet -mt1 @mate1 -mt2 @mate2 -D -an genes.gtf -Pi -F -M -A genome.fa. The output tables with counts, coordinates and annotations were merge by locus d for further analysis.
Ingenuity Pathway Analysis
The Network and Canonical Pathway Analysis were generated through the use of IPA (QIAGEN Inc., https://www. qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) (Krä mer et al., 2014) . The list of differentially expressed genes (3875) generated by DeSeq2 of RR VSMC versus [RR KO, NN, NN KO] was input on IPA software and analyzed. Canonical Pathways with -log(p value) > 3 and with an absolute Z-score value of at least 2 were analyzed. For Canonical pathways and Network analysis shapes and lines were modified for simplicity.
Immunocytochemistry
Cultured cells were fixed using 4% paraformaldehyde in PBS. Fixed samples were treated with 0.5% Triton X-100 in PBS for cytoplasmic and nuclear staining. Cells were then blocked with 5% FBS in PBS for 1 hour at room temperature. Blocking solution was aspirated and replaced with primary antibody in blocking buffer and incubated approximately 2 hours at room temperature, or overnight at 4C. Primary antibody solution was then aspirated, fixed samples washed three times with PBS, secondary antibody and DAPI in blocking buffer added to the washed samples, and incubated 45min-1hr at room temperature. Three additional PBS washes were performed after secondary antibody incubation, and the samples imaged with fluorescence microscopy. In the case of phalloidin staining, the secondary antibody-treated samples were incubated for 30min with the phalloidin-Alexa conjugate (following manufacturer protocol), followed by two washes with PBS. Stained samples were imaged on a Nikon Eclipse Ti at 4x, 10x, and/or 20x magnification. Antibodies used include: Tra-1-81 (Millipore Cat. MAB4381, 1:500), TRA-1-60 (Millipore Cat. MAB4360, 1:500), Nanog (Abcam Cat. ab21624, 1:200), a-Smooth Muscle Actin (Sigma Cat. A5228, 1:1000), Phalloidin (Life Tech Cat. A12379, 1:50), Nkx2.5 (SCBT Cat. sc-14033, 1:200), Transgelin (TAGLN; Abcam Cat. ab14106, 1:500), Calponin1 (CNN1; Sigma Cat. C2687, 1:20,000).
DNA content Analysis
Cells at day 5 of VSMC differentiation were detached by using TrypLE Express (Life Technologies), spun at 200 g for 5 minutes. Pellet was washed in PBS and spun again. After PBS removal 70% cold EtOH was added dropwise while vortexing. Cells were incubated for 30 minutes at 4 C, and then spun at 200 g for 5 minutes at 4 C. After washing twice with PBS, pellets were resuspended in Propidium Iodide staining solution (0.1%Triton in PBS + 20ug/ml PI + 200ug/ml RNase A). Staining was performed overnight, and FACS analysis was performed the next day.
Cell Adhesion Strength Assay 25 mm glass coverslips (Fisher Scientific, St. Louis, MO) were cleaned via sonication with ethanol and DI water before being incubated with 0.1% gelatin in DI H 2 O (StemCell Technologies, Vancouver, CAN) for 60 minutes at room temperature. After allowing cells to attach for 24 hours at 37 C and 5% CO 2 , coverslips were then mounted on a custom-built spinning disc device (García et al., 1997) in a temperature-controlled spinning buffer (37 C) containing phosphate buffered saline with 0.5 mM MgCl 2 and 1 mM CaCl 2 (Cellgro, Manassas, VA) and 4.5 mg/mL dextrose (Fisher). Coverslips were spun for 5 min at defined angular velocities (2000, 3000, and 5000 rpm), fixed with 3.7% formaldehyde immediately after spinning, stained with 1:5000 Hoescht in DI H 2 O for 15 minutes, and mounted with Fluoromount-G (Southern Biotech, Birmingham, AL). To obtain quantitative information of adhesion strength, coverslips were imaged at 10x magnification on a Nikon Ti-S microscope with motorized stage ($1000 individual images stitched together with Metamorph 7.6 software and custom macros) and cells positions from analyses performed by a custom written MATLAB script . The shear stress applied to each cell was computed based on their radial position using:
Eqn (1) where r is the radial position from the center of the disk, r is the buffer density, m is the buffer viscosity and u is the rotational speed (Wen et al., 2014) . Cell density as a function of radial position is normalized to a coverslip not subjected to shear and the center of each sheared coverslip. A sigmoidal fit is used to quantify adhesion strength, i.e., the point where 50% of cells remain attached.
Traction Force Microscopy 12 mm glass coverslips (Fisher) were oxidized via UV/ozone exposure (BioForce Nanosciences, Ames, IA) followed by functionalization with 20 mM 3-(trimethoxysilyl)propyl methacrylate (Sigma-Aldrich, St. Louis, MO) in ethanol. A polymer solution containing 10%/0.1% acrylamide/bis-acrylamide (Fisher), 1% v/v of 10% ammonium persulfate (Fisher), and 0.1% v/v of N,N,N',N'-Tetramethylethylenediamine (VWR International, Radnor, PA) was prepared. In addition, 2% v/v fluorescent 580/605 0.2 mm microspheres (Invitrogen, Carlsbad, CA) were added to the pre-polymer solution. 7 mL of polymerizing hydrogel solution was sandwiched between a functionalized coverslip and a dichlorodimethylsilane-treated glass slide and was allowed to polymerize for 15 minutes. 0.1% gelatin (StemCell Technologies) was coupled to the surface using N-sulphosuccinimidyl-6-(4'-azido-2 0 -nitrophenylamino) hexanoate (sulfo-SANPAH) as a protein-substrate linker. Hydrogels were incubated in 0.2 mg/ml sulfo-SANPAH (Fisher) in sterile 50 mM HEPES pH 8.5, activated with UV light (wavelength 350 nm, intensity 4 mW/cm 2 ) for 10 minutes, washed three times in HEPES, and then incubated in 0.1% gelatin (BD Biosciences) overnight at 37 C. Following UV sterilization, cells were cultured on substrates for 48 hours at 37 C and 5% CO 2 . The microspheres underneath selected live cells were imaged with a 60x water confocal objective using a Nikon Eclipse TI-S microscope equipped with a CARV II confocal system (BD Biosciences) and motorized stage. Images were acquired on a Cool-Snap HQ camera (Photometrics) controlled by Metamorph (Molecular Devices). Cells were released with 2.5% trypsin (Fisher) and the same confocal stacks acquired. Bead displacements were determined using a particle image velocimetry script in MATLAB (MathWorks) and normalized to cell area.
Gel Contraction Assay
Cells were detached from substrates using Tryple (Thermo Fisher Scientific, Waltham, MA) as previously described and suspended in 1x DMEM (Thermo) containing 10% fetal bovine serum (Gemini Bio-products, West Sacramento, CA). 80 mL of 6x DMEM, 400 mL of 3 mg/mL type 1 rat tail collagen (Corning Incorporated, Corning, NY), and 120 mL of cell suspension at a final concentration of 0.2 million cells/mL were placed in a 24-well plate and allowed to polymerize at 37 C and 5% CO2 for one hour. To assess smooth muscle cell contractility in the presence of contractile agonist and antagonist, a final concentration of 10 nM bradykinin or 0.5 mM cytochalasinD (Sigma-Aldrich, St. Louis, MO) was added to cell suspension media. After 24 hours at 37 C and 5% CO2, 1mL of 1x DMEM + 10% FBS was added to each well. Images of the gels were taken at each subsequent 24 hour period until 8 days in culture. The diameter of each gel was measured using ImageJ software (NIH, Bethesda, Maryland) and normalized to the initial gel diameter on day 0.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
Statistical analyses were performed using GraphPad Prism5 and detailed in the corresponding figure legends and number experiments and samples for each experiments is detailed in Table S2 . Data were analyzed by one-way ANOVA followed by Bonferroni's multiple comparison post hoc test or t test as specified in the corresponding figure legends. Data for significance of CAD-associated genes from GWAS studies in Figure 7 were analyzed with binomial distribution test in R.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq data reported in this paper is GEO: GSE120099
Cell 175, 1796-1810.e1-e9, December 13, 2018 e9 Figure S1 . 9p21.3 CAD Deletion iPSCs Generation and Validation, Related to Figure 1 (A) Schematic of the genotyping PCR performed to detect 9p21 deletion and genotyping results. Two possible products (400bp WT, and 300bp KO) can be amplified in the presence or absence of the intact 9p21 region. The panel shows the genotype of 2 WT, 2 heterozygous deleted and 2 KO iPSC clones derived from both donors. (B) (legend continued on next page) (E) In scale figure showing complete CAD risk region difference between the two patients validated by deep Next Generation Sequencing. The index SNPs of the risk status are highlighted with yellow, and non-risk specific SNPs are highlighted in green. Only homozygous SNPs are shown. 83 total differences were observed between individuals, 57 are directly associated with 9p21 risk status (R-squared > = 0.8 with index allele rs23832207). For the remaining 26 SNPs, 25 are common variants (R-squared < 0.8, allele frequency > 5%), and one is a rare variant (rs72652428) with frequency < 1%.
Supplemental Figures
(legend on next page) Details about number of lines can be found in Table S2 . (B) Heatmap of key genes in three stages of VSMC differentiation: iPSCs, MP and terminally differentiated VSMCs. (C) Heatmap showing hierarchical clustering of transcriptome similarity of MP at day 3. (D) Heatmaps of genes differentially expressed in MP at D3 from the GO category Embryo development (p = 2.58E-02, fold enrichment 2.57), Muscle organ development (p = 3.44E-05, fold enrichment 2.55), Biological adhesion (p = 1.63E-04, fold enrichment 1.94). Figure S3 . Terminally Differentiated VSMC, Related to Figure 3 (A) Heatmap showing hierarchical clustering of transcriptome similarity of VSMC at D17. (B) Heatmaps showing genes differentially expressed in the presence of RR 9p21 at D17 (fold change > 2), included in the following GO categories: Regulation of cell cycle (GO:0051726), (fold enrichment = 9.03, p = 9.19E-04); DNA recombination (GO:0006310) (fe = 5.87, p = 2.57E-03); DNA replication (GO:0006260) (fe = 4.92, p = 6.86E-09); DNA metabolic process (GO:0006259) (fe = 3.33, p = 3.94E-09); DNA repair (GO:0006281) (fe = 3.07, p = 8.45E-03); chromatin organization (GO:0006325) (fe = 2.47, p = 4.28E-02); cell cycle (GO:0007049) (fe = 2.23, p = 2.60E-09). Values are Z-score. 
Schematic of ANRIL splicing isoforms. Light gray represents ANRIL isoforms previously described. Dark gray highlights isoforms present in VSMCs in our study, based on aligning RNA sequencing reads across exon junctions. ANRIL 11-12 isoforms highlighted in red were confirmed also by RT-PCR. RNaseq results (summarized in Figure 5A ) show novel alternative splicing in isoforms 2 and 3. In particular, ANRIL 2 isoform does not contain exon 2 and 4, and there is evidence for possible usage of exon 12 in RR.
(legend continued on next page) (C) Agarose gel showing RT-PCR results for ANRIL isoforms. PCR was performed using primers spanning exon 1 through exon 13, or exon 1 through 19. cDNA template was from the RR1 donor. On the left side DNA ladder, arrows show isoforms identified after Sanger sequencing of the gel extracted bands. (D) Quantification of ANRIL expression using primers in the 5-6 exon junction (left) and within exon 13(right) (relative to samples presented in Figure 5B ). (E) qRT-PCR detecting ANRIL expression (exon 5-6 junction) in NN KO cells after rtTA, rtTa+ ANRIL 11 or 12 transduction at passage 1, 2, 4. Graph shows expression of ANRIL relative to rtTA control at p1. PPIA was used as reference gene. Data are mean of two independent replicates. Bar is SEM. *p < 0.05, **p < 0.01 ***p < 0.001. Figure S5 . Validation of Gene Expression Analysis on Additional iPSC-Derived VSMCs from Independent Donors, Related to Figure 6 (A) RT-PCR for ANRIL performed with primers spanning exons1 through 13. Samples used are 3 RR and 3 NN VSMC (D17) from donors described in Figures 1  and 6 and Table S2 . Gels show two RT-PCR of 42 cycle after a 26 cycle RACE from 2 independent library preparations. Arrows of different colors represent different ANRIL isoforms (A11, A12, A13). ''NN 3*'' in the gel on the right is an additional reaction of NN 3 sample in which more DNA was used. Details about exon composition of the isoforms can be found in Figure S4B . (B) qRT-PCR analysis of adhesion molecule genes was performed on additional RR and NN lines described in Figure 6 (mean ± SEM). *p < 0.05 and **p < 0.01 unpaired t test.
(legend on next page) Figure S6 . Relevance for Cardiovascular Disease, Related to Figure 7 
